Efficacy and safety analysis of TACE combined with lenvatinib and icaritin in unresectable hepatocellular carcinoma with poor performance status
Haohao Lu, Bin Liang, Chuansheng Zheng, Yanyan Cao, Xiangwen Xia · 2026
Read Efficacy and safety analysis of TACE combined with lenvatinib and icaritin in unresectable hepatocellular carcinoma with poor performance status by Haohao Lu, Bin Liang, Chuansheng Zheng, Yanyan Cao, Xiangwen Xia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471543.txt.
Description
Lu and co-authors studied a triple therapy for liver cancer patients too frail for standard systemic treatment, combining artery-directed chemotherapy with two oral drugs. Their 2026 analysis covered 49 patients with unresectable hepatocellular carcinoma and poor performance status treated between June 2022 and December 2023, 21 receiving the combination and 28 receiving TACE alone.
Tumors responded far more often with the combination: objective response was 66.7% against 28.6% with TACE alone, and disease control reached 85.7% versus 53.6% between the groups. Median time without progression stretched to 8.6 months on the triple therapy versus 4.1 months on TACE alone, with a hazard ratio of 0.316 favoring the combination. More combination patients also reported meaningful improvement in their physical condition.
Catalog record
| CREATOR | Haohao Lu, Bin Liang, Chuansheng Zheng, Yanyan Cao, Xiangwen Xia |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |